Then, we performed flow cytometry (FC) to analyze the viability dye (positive indicates dying or dead cells) and CD44 expression, as well as an AML blast marker to determine the therapeutic efficacy of the combination in vitro. Here, CD44 is linked to acute myeloid leukemia.